Pasar al contenido principal

HERRAMIENTAS PARA EL ESTUDIO DE INTERACCIONES PROTEINA-PROTEINA: APLICACION AL ESTUDIO Y VALIDACION DE LA PROTEINA DREAM COMO DIANA TERAPEUTICA

BFU2015-67284-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Tailoring chemical tools for modulating the Kv4.3/KChIP3 interaction

  • Cercós, Pilar
  • Peraza, Diego A.
  • González, Teresa
  • Mellström, Britt
  • Herranz, Rosario
  • Martín-Martínez, Mercedes
  • Naranjo, José Ramón
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado al VI Meeting de la Red Española de Canales Ióniocs (RECI), celebrado en Santiago de Compostela del 6 al 8 de septiembre de 2017., KChIP-3 (potassium channel interacting protein-3), also known as DREAM (Downstream Regulatory Element Antagonist Modulator) or calsenilin, is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival.1 As an auxiliary protein in the plasma membrane, KChIP-3 interacts with, and regulates, among others, the gating of KV4 potassium channels, L- and T-type voltage-dependent calcium channels, NMDA receptors and the transcriptor factor ATF6, which is involved in the unfolding protein response machinery. Considering that altered neuronal calcium homeostasis and the accumulation of poorly folded proteins are common features of many neurodegenerative pathologies, the KChIP-3 modulation could open new avenues for the treatment of different neurodegenerative diseases. However, up to now, only three KChIP-3 binding molecules have been identified. Hence, there is a clear need for the development of chemical tools to modulate and characterize KChIP-3 activity and its interactions. In this communication we report the rational design and synthesis of new KChIP-3 ligands as pharmacological tools to study its protein-protein interaction network, focusing on those interactions involved in neurodegenerative pathologies., This work was supported by Ministerio de Economia y Competitividad (BFU2015-67284-R) and CSIC (201580E073-PIE)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Fine-tuning DREAM signaling using chemical tools for neurodegenerative disease treatment

  • Gutiérrez-Rodríguez, Marta
  • Cercós, Pilar
  • Izquierdo García, Carolina
  • Peraza, Diego A.
  • López-Hurtado, Alejandro
  • González Pérez, Paz
  • Dopazo, Xose M.
  • Herranz, Rosario
  • González, Teresa
  • Mellström, Britt
  • Martín-Martínez, Mercedes
  • Naranjo, José Ramón
  • Valenzuela, Carmen
Resumen del trabajo presentado al 6th European Chemical Biology Symposium ECBS/LS-EuChemS, celebrado en Madrid (España) del 3 al 5 de abril de 2019., DREAM (Downstream Regulatory Element Antagonist Modulator), also known as KChIP-3 or calsenilin, is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival. As an auxiliary protein in the plasma membrane, DREAM interacts with, and regulates, the gating of KV4 potassium channels, L- and T-type voltage-dependent calcium channels, NMDA receptors and the transcriptor factor ATF6, which is involved in the unfolding protein response machinary. Considering that altered neuronal calcium homeostasis and the accumulation of poorly folded proteins are common features of many neurodegenerative pathologies, the DREAM modulation could open new avenues for the treatment of neurodegenerative diseases. We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington's disease (HD)[1]. However, up to now, only three DREAM binding molecules have been identified. Hence, there is a clear need for the development of chemical tools to modulate and characterize DREAM activity and its interactions. In this communication we will report the identification of novel DREAM modulators by following a multidisciplinary strategy that involves structure-based design, organic chemistry, site-directed mutagenesis and in vitro and in vivo experiments. Our findings open a new avenue in the search of effective treatments of neurodegenerative diseases., Spanish Ministery of Economy, Industry and Competitivity (AEI-FEDER, EU grants): BFU2015-67284-R, SAF2017-89554-R, SAF2016-75021-R, SAF2015-66275-C2-2-R; Instituto de Salud Carlos III CIBERNED and CIBERCV programs; the Madrid regional government/Neurodegmodels; and CSIC PIE 201580E073., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of IQM-266, a novel DREAM ligand that modulates Kv4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos: Symposium 6: Drug Discovery and ion channel Pharmacology, celebrado en Cáceres del 15 al 17 de mayo de 2019., Funded by BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017-89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV), SAF2015-66275-C2-2-R (to MM-M); UCM grant: PR75/18-21593 (to AA); and CSIC grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Electrophysiological effects of IQM-266 on KV1.5 channels

  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Cercós, Pilar
  • Sánchez, Sara A.
  • Peraza, Diego A.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos, celebrado en Cáceres del 15 al 17 de mayo de 2019., The outward potassium current IKur is the main responsible of the atrial repolarization process and it is generated by the activation of KV1.5 channels, widely expressed in human atria. It is known that mutations in KCNA5 gene, which induce both gain- and loss-of-function in KV1.5 channel, enhance atrial fibrillation susceptibility. Thus, these channels represent a pharmacological target for the development of antiarrhythmic drugs useful in the treatment of supraventricular arrhythmias. KV1.5 channels assembly with several regulatory subunits such as KVβ and KChIPs (KV Channel Interacting Proteins). It has been described that KChIP2 physically interacts with KV1.5 and reduces KV1.5 cell surface expression levels. Our research group has demonstrated that IQM-266 inhibits the current generated by the activation of KV4.3 and KV4.3/KChIP2, being the effects more marked when KChIP2 is present. The aim of the present study is to analyze the effects of IQM-266 on KV1.5 channels. In order to achieve these objectives, HEK293 cells transiently expressing KV1.5 were used. Currents were recorded using the whole-cell configuration of the patch-clamp technique. The effects of IQM-266 on KV1.5 currents were concentration-dependent with an IC50 of 11 μM (n=24). Block induced by IQM-266 (20 μM) sharply increased within the membrane voltage range of the channel activation, arising a maximum degree of block at +20 mV that remained constant at more positive membrane potentials. This compound at 20 μM produced a timedependent block, inducing a: 1) faster inactivation (τ = 305.8±47.6 ms vs. 168.0±13.4 ms, in the absence and in the presence of IQM-266, respectively, n=9, p<0.01), and 2) slower deactivation kinetics, increasing the contribution of the slow component of deactivation to the total process (0.36±0.05 vs. 0.57±0.05, in the absence and in the presence of IQM-266, respectively, n=11, p<0.01). These results are consistent with an open channel block mechanism. Finally, IQM-266 (20 μM) enhanced the degree of use-dependent block of the current (25.6±2.7% vs. 77.6±4.9%, in the absence and in the presence of IQM-266, n=5, p<0.001). These phenomenon was explained by a slowing of the recovery process in the presence of the compound (991.1±131.8 ms vs. 5132.8±763.6 ms in the absence and in the presence of IQM-266, respectively, n=4, p<0.05). Thus, IQM-266 is able to bind KV1.5 channels, although with less affinity than that shown in KV4.3/KChIP2 complexes., Supported by SAF2016-75021-R and CSIC PIE201820E104 to CV, BFU2015-67284-R and CSIC PIE201880E109 to MGR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

IQM-PC332, a novel DREAM ligand with analgesic effect on experimental peripheral nerve injury- and diabetes-induced pain

  • Socuéllamos, Paula G.
  • Cercós, Pilar
  • Olivos-Oré, Luis Alcides
  • Barahona, María Victoria
  • Bosch, Gerardo
  • Naranjo, José Ramón
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
  • Artalejo, Antonio R.
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos, celebrado en Cáceres del 15 al 17 de mayo de 2019., Neuropathic pain is a form of chronic pain arising from damage to the nerves that sense, transmit or process information about environmental stimuli. Given its growing prevalence and common refractoriness to conventional analgesics, the development of new drugs with pain relief effect constitute a prominent clinical need. In this respect, drugs that reduce activity of sensory neurons by modulating ion channels hold the promise to become effective analgesics. Here we have used two models of neuropathic pain, namely the chronic constriction injury of the sciatic nerve (CCI) and the streptozotocin-induced diabetic neuropathy, to evaluate the mechanical antiallodynic effect of IQM-PC332, a novel Downstream Regulatory Element Antagonist Modulator (DREAM)/KChIP3/calsenilin ligand potentially affecting DREAM modulated ionic currents like potassium IA and ICav. IQM-PC332 exerted a mechanical antiallodynic effect following intraperitoneal (I.P; DE50 of 0.06 μg/kg, Emax of 65%) and intraplantar (DE50 of 0.24 mg, Emax of 68%) administration in the CCI, model. Likewise, IQM-PC332 2 μg/kg I.P. significantly reduced mechanical allodynia in diabetic animals. Interestingly, no effect of IQM-PC332 on glucose levels from both CCI and diabetic animal could be observed at analgesic doses. The effects of IQM-PC332 on INav, ICav, IA, and the electrical excitability in neurons isolated from dorsal root ganglia (L4-L6; DRG) were also studied with the patch-clamp technique. IQM-PC332 reduced peak amplitudes of ICav from both Control and CCI animals with CI50 (@ +10 mV) of 78 μM y 40 μM, respectively. At variance, IQM-PC332 did not exert any effect on INav in the concentration range from 0.01 to 50 μM. PC332 10 μM also inhibited IA in DRG neurons from CCI animals, this effect being larger with membrane depolarization (≈ 50% inhibition at -10 mV). Interestingly, in about 55% of the neurons, IQM-PC332 slowed inactivation of IA. In accordance with its effects on ion currents, IQM-PC332 10 μM reduced the time to the first action potential (AP) evoked by current injection while decreasing the amplitude and duration of the after hyperpolarization that followed after APs within a train. However, no clear effect on instantaneous frequency of AP could be observed. It is suggested that inhibition of Ca2+ entry through Cav channels coupled to neurotransmitter release from peripheral and central terminals of nociceptive neurons may underlie the analgesic effect of IQM-PC332., Supported by Universidad Complutense, grant PR75/18-21593 to ARA, SAF2016-75021-R and PIE201820E104 to CV, BFU2015-67284-R and PIE201880E109 (CSIC grant) to MGR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Naphthalimide-Based Fluorescence Macrophage Sensors. Localization Selectivity through Substituent Chemical Manipulation

  • Herranz, Rosario
  • Fueyo-González, Francisco
  • González-Verdejo, Juan A.
  • Orte, Angel
  • Fernández-Gutiérrez, Mar
The 1,8-naphthalimide scaffold is found among the most fruitful structures in the design of fluorophores with application in the development of fluorescence biosensors, due to its favorable photophysical properties, such as strong absorption and emission, large Stokes shifts, and photostability[1]. Considering that introduction of a nitrogen atom into the 1,8-naphtalimide skeleton could red-shift the fluorescence emission and increase water solubility, we have recently studied the design, synthesis and photophysical properties of 8-methoxy-4,5-quinolimides[2]. The photophysical properties of both scaffolds depend on the attached substituents and can be tuned by chemical manipulation. We have synthesized and will communicate new naphthalimide (A) and quinolimide (B) derivatives with a dimethylaminoethyl chain at the imide nitrogen atom, which behave as macrophage fluorescence sensors. Depending on the nature of the R substituent, these fluorophores can be used to imagine either the macrophage cytoplasm or the nucleus. The nucleus sensors bind DNA as intercalants., The work was supported by the Spanish Ministerio de Economía y Competividad grants SAF2012-32209, FU2015-67284-R, CTQ2017-85658-R, and the CSIC grant 201580E07